TQB2934 / Sino Biopharm - LARVOL DELTA

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study (ASH 2025) - P1 | "TQB2934, a novel 2+1 BCMA bispecific antibody, has demonstrated a manageable safetyprofile and encouraging clinical activity at doses ≥20mg in heavily pretreated RRMM patients. Theseresults position TQB2934 as a promising new therapeutic option for this challenging patient population."

Clinical • P1 data • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia

A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients (clinicaltrials.gov) - P1/2 | N=70 | Not yet recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

New P1/2 trial • Amyloidosis

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple (ASH 2024) - P1 | "Conclusions : TQB2934, a 2+1 BCMA bispecific antibody, has shown manageable safety profiles and encouraging clinical activity at higher doses in patients with heavily pretreated RRMM. These results support further clinical evaluation and enrollment in the phase 1 study is ongoing."

Clinical • Monotherapy • P1 data • Anemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia

A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

IO biomarker • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma

Three new category 1 drugs with new indications from Zhengda Tianqing were approved for clinical trials [Google translation] (Sina Corp) - "On April 8, three innovative Class 1 antibody drugs of Zhengda Tianqing were approved for clinical trials for new indications. These three new drugs are BCMA/CD3 bispecific antibody TQB2934, EGFR/c-Met bispecific antibody TQB2922 and ST2 monoclonal antibody TQC2938. The newly added indications are the treatment of systemic light chain (AL) amyloidosis in adults, the treatment of advanced malignant tumors in combination with other marketed anti-tumor drugs, and the treatment of seasonal allergic rhinitis."

New trial • Allergic Rhinitis • Amyloidosis • Hematological Malignancies

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • IL10 • IL2 • IL6

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects (clinicaltrials.gov) - P1 | N=140 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

IO biomarker • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology • IL10 • IL2 • IL6